search
Back to results

Research on the Blood- Cooling - Toxin - Removing - Stasis - Dispersing Protocol Evaluation of Hench-schonlein Purpura

Primary Purpose

Purpura, Schoenlein-Henoch

Status
Unknown status
Phase
Phase 2
Locations
China
Study Type
Interventional
Intervention
Placebo
"ziying" granules
Sponsored by
Liaoning University of Traditional Chinese Medicine
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Purpura, Schoenlein-Henoch focused on measuring Hench-schonlein purpura, Renal damage, Relapse, End event, TCM syndrome

Eligibility Criteria

5 Years - 18 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • To comply with the diagnostic standard of purpura in TCM and Hench-schonlein purpura in western medicine;
  • To comply with the diagnostic standard of TCM syndrome differentiation;
  • Age between 5 and 18;
  • without similar herbal treatment a week before being included;
  • Informed Consent Form is required to be singed.

Exclusion Criteria:

  • Fall short of the diagnostic standard of purpura in TCM and Hench-schonlein purpura in western medicine;
  • Fall short of the diagnostic standard of TCM syndrome differentiation;
  • Older then 18 years or younger then 5years;
  • Take similar herbal treatment within a week before being included;
  • Can not take the drug according to the regulation or follow-up on time
  • Patients combine serious primary disease in respiratory、gastrointestinal、hemopoietic、renal,or psychosis,or pestilence;
  • Allergic to drugs of this research or others;
  • human subject of other clinical research in the nearly tow weeks.

Sites / Locations

  • ZhangjunRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Placebo Comparator

Experimental

Arm Label

placebo

Drug:"ziying"

Arm Description

Outcomes

Primary Outcome Measures

whether endpoint such as renal damage or disease recurrence appears in the participants.
Endpoint is a mark of termination or completion. In this clinical research, the renal damage and disease recurrence that constitutes the target outcomes of the trial.

Secondary Outcome Measures

whether the TCM syndrome of participants disappears after treatment.
Optimize the TCM scheme of syndrome differentiation and treatment of HSP in line with the idea of blood- Cooling - Toxin - Removing - Stasis - Dispersing, under the path of combination between disease differentiation and syndrome differentiation In the process of disease of a series of function, metabolism and morphological structure changes caused by the subjective feeling of abnormal patient as symptoms.

Full Information

First Posted
January 25, 2010
Last Updated
September 7, 2010
Sponsor
Liaoning University of Traditional Chinese Medicine
Collaborators
Dongzhimen Hospital, Beijing, Shenyang Hospital of Integrated Traditional and westen Medicine, Dalian Children's Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT01104428
Brief Title
Research on the Blood- Cooling - Toxin - Removing - Stasis - Dispersing Protocol Evaluation of Hench-schonlein Purpura
Official Title
Research on the Blood- Cooling - Toxin - Removing - Stasis - Dispersing Protocol Evaluation of Hench-schonlein Purpura
Study Type
Interventional

2. Study Status

Record Verification Date
September 2010
Overall Recruitment Status
Unknown status
Study Start Date
November 2009 (undefined)
Primary Completion Date
December 2011 (Anticipated)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
Liaoning University of Traditional Chinese Medicine
Collaborators
Dongzhimen Hospital, Beijing, Shenyang Hospital of Integrated Traditional and westen Medicine, Dalian Children's Hospital

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Due to high incidence of renal damage by Hench-schonlein Purpura(HSP) is the key to affect prognosis, this project moves the research emphasis forward in line with the idea of "prevention of progress of disease", Which concerns on Traditional Chinese Medicine(TCM) clinical research scheme evaluation of HSP, evaluates the renal damage and disease recurrence as the end event, and comes to the evaluation through the comparative study that the vantage point of the scheme of syndrome differentiation and treatment in detoxification, cooling blood and removing blood stasis to the conventional treatments can reduce kidney damage and recurrence rate.
Detailed Description
Target:Optimize the TCM scheme of syndrome differentiation and treatment of HSP in line with the idea of blood- Cooling - Toxin - Removing - Stasis - Dispersing under the path of combination between disease differentiation and syndrome differentiation, and regards reducing the rate of the recurrence of HSP and kidney damage as the end point of evaluation indexes, to evaluate the clinical efficacy of the scheme scientifically. Main research contents: Retrospective case investigation, analysis and research on literature, research on clinical assessment of the scheme of syndrome differentiation and treatment. Methods:With a series of compounds as the main interference factors, choosing the sample estimation of superiority design and adopting the test methods of randomized, double-blind, placebo-controlled to carry out the research of multicenter clinical efficacy evaluation. It summarizes the advantages and rules of syndrome differentiation and treatment in TCM by means of the comparative study, which provides technical guidelines for the industry and sets an example to summarize the key common technology of clinical research, and also improves the evaluation level of TCM clinical research and efficacy.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Purpura, Schoenlein-Henoch
Keywords
Hench-schonlein purpura, Renal damage, Relapse, End event, TCM syndrome

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
256 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
placebo
Arm Type
Placebo Comparator
Arm Title
Drug:"ziying"
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
granules, <10years,10g,Three times a day,take orally >10years,20g,Three times a day,take orally fore weeks a period,Observe 2 periods
Intervention Type
Drug
Intervention Name(s)
"ziying" granules
Intervention Description
granules, <10years,10g,Three times a day,take orally >10years,20g,Three times a day,take orally fore weeks a period,Observe 2 periods
Primary Outcome Measure Information:
Title
whether endpoint such as renal damage or disease recurrence appears in the participants.
Description
Endpoint is a mark of termination or completion. In this clinical research, the renal damage and disease recurrence that constitutes the target outcomes of the trial.
Time Frame
6 months
Secondary Outcome Measure Information:
Title
whether the TCM syndrome of participants disappears after treatment.
Description
Optimize the TCM scheme of syndrome differentiation and treatment of HSP in line with the idea of blood- Cooling - Toxin - Removing - Stasis - Dispersing, under the path of combination between disease differentiation and syndrome differentiation In the process of disease of a series of function, metabolism and morphological structure changes caused by the subjective feeling of abnormal patient as symptoms.
Time Frame
1 month

10. Eligibility

Sex
All
Minimum Age & Unit of Time
5 Years
Maximum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: To comply with the diagnostic standard of purpura in TCM and Hench-schonlein purpura in western medicine; To comply with the diagnostic standard of TCM syndrome differentiation; Age between 5 and 18; without similar herbal treatment a week before being included; Informed Consent Form is required to be singed. Exclusion Criteria: Fall short of the diagnostic standard of purpura in TCM and Hench-schonlein purpura in western medicine; Fall short of the diagnostic standard of TCM syndrome differentiation; Older then 18 years or younger then 5years; Take similar herbal treatment within a week before being included; Can not take the drug according to the regulation or follow-up on time Patients combine serious primary disease in respiratory、gastrointestinal、hemopoietic、renal,or psychosis,or pestilence; Allergic to drugs of this research or others; human subject of other clinical research in the nearly tow weeks.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
zhang shaoqing, Master
Phone
86-024-86291599
Email
yanzi8164@163.com
First Name & Middle Initial & Last Name or Official Title & Degree
yang guanqi, Master
Phone
86-024-86291599
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
zhang jun, master
Organizational Affiliation
First Affiliated Hospital of Liaoning University of Traditional Chinese Medicine
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
zhao lijun, master
Organizational Affiliation
First Affiliated Hospital of Liaoning University of Traditional Chinese Medicine
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
wang shaojie, master
Organizational Affiliation
Dalian Children's Hospital
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
ma liming, master
Organizational Affiliation
First Affiliated Hospital of Liaoning University of Traditional Chinese Medicine
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
li tienan, master
Organizational Affiliation
Shenyang Hospital of Integrated Traditional and westen Medicine
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
xu rongqian, master
Organizational Affiliation
Dongzhimen Hospital, Beijing
Official's Role
Principal Investigator
Facility Information:
Facility Name
Zhangjun
City
Shenyang
State/Province
Liaoning
ZIP/Postal Code
110032
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
zhang shaoqing, master
Phone
86-024-86291599
Email
yanzi8164@163.com
First Name & Middle Initial & Last Name & Degree
yang guanqi, master
Phone
86-024-86291599

12. IPD Sharing Statement

Learn more about this trial

Research on the Blood- Cooling - Toxin - Removing - Stasis - Dispersing Protocol Evaluation of Hench-schonlein Purpura

We'll reach out to this number within 24 hrs